



Abteilung für Klinische Pharmakologie
Medizinische Klinik und Poliklinik IV
Campus Innenstadt

Leiter: Prof. Dr. Stefan Endres



Klinikum der Universität München · Abteilung für Klinische Pharmakologie ·
Lindwurmstraße 2a · 80337 München

Pedro Romero, M.D.
Editor-in-chief
Journal for the Immunotherapy of Cancer

Univ.-Prof.
Dr. med. S. Kobold
Oberarzt
Telefon 089 44005 7325
Telefax 089 44005 7330
Sebastian.kobold@med.uni-
muenchen.de

www.klinische-
pharmakologie.de

Lindwurmstraße 2a
D-80337 München

München,
November 7th 2019

Submission of a revised manuscript JITC-D-19-00714 for consideration for publication in Journal for Immunotherapy of Cancer

Dear Dr. Romero,

Please find enclosed our revised manuscript entitled “6th Immunotherapy of cancer conference (ITOC): advances and perspectives, a meeting report” for consideration for publication in Journal for Immunotherapy of Cancer.

We want to thank the reviewers for the helpful comments which have helped to strengthen our manuscript. Please find below our point to point reply to the reviewers’ comments.

Reviewer #1: The manuscript represents a meeting report on 6th Immunotherapy of cancer conference (ITOC), which was held in April 2019 in Vienna, Austria. This manuscript reflects the various topics of this meeting, in particular microenvironment and metabolism, emerging concepts and new agents, combination therapy, preclinical models, precision medicine meets immunotherapy and anticancer vaccines. The major important information of the talks were summarized and put into the context of the current research and immunotherapies. The manuscript is well written and comprehensive.

There are a few minor comments meant to enhance the report. First of all there are no keywords representing the main content of the article.

We added keywords that represent the content of the article.

Moreover, a list of abbreviations is required from the Journal.

We also added a list of abbreviations used through the text.

Maybe few introductory sentences and summary sentence of each section would make the report read more cohesively.

Unfortunately, the word count limit of the format does not allow introductory and summary sentences. We instead aimed at clarifying formulations and wording for in-depth summary of each talk presented at the conference.

KLINIKUM DER UNIVERSITÄT MÜNCHEN

Reviewer #2: In this paper, the Authors summarize the 6th Immunotherapy of cancer conference (ITOC). I have not specific criticisms, however, the reports of the various speakers are excessively summarized and the information for the reader is concise and of little impact.

We carefully revised each section and increased the scientific depth of each summary and added more details relevant to the critical points of the talks within the given word limit. It would allow clinicians and researchers get a comprehensive overview of novel findings that were reported and search specifically for the topics that are of interest.

In order to improve the quality of the paper, each intervention should be described in greater depth with more data. At least 1 figure or table should be included.

We summarized each talk in greater depth and with more data. We also included one figure that graphically summarized the key points of the talks presented during sessions.

We thank the editor and the reviewers for their work and helpful comments and suggestions.

We hope we could address all reviewer concerns, and our manuscript will now be deemed suitable for publication in the Journal for Immunotherapy of Cancer.

Thanking for your consideration, we are looking forward to the feedback.

Best regards



Univ.-Prof. Dr. med. Sebastian Kobold